The S A S Foundation for Cancer Research focuses almost exclusively on translational and biomedical research targeting pancreatic cancer, funding laboratory and immunotherapy projects that bridge basic science and clinical application. Their giving concentrates on established cancer centers and disease-specific foundations, supporting mechanistic tumor biology studies and personalized immunotherapy development. Grants emphasize project-specific research at institutions with strong clinical research capacity.
S a S Foundation for Cancer Research Inc has funded a repeated set of cancer research projects centered on pancreatic disease, with additional support for studies on treatment resistance and immunotherapy. One of its clearest patterns is backing the same research themes across multiple years, including work on HNF1A in pancreatic ductal adenocarcinoma and on mechanisms of drug resistance in triple-negative breast cancer. The foundation also funded a translational convergence program for personalized immunotherapy for pancreatic cancer patients at Johns Hopkins University, showing interest in projects that connect laboratory work to clinical application. Its recent grants also include support for Roswell Park Alliance Foundation in Buffalo, where the foundation has backed disease-focused research questions tied to tumor growth, microenvironment dynamics, and chemotherapy resistance. Across the grants listed here, the foundation appears to favor project-specific research awards rather than broad operating support, and the grantees are established research organizations with strong cancer research capacity. The overall picture is of a funder concentrated on translational biomedical research that seeks to move cancer science toward treatment-relevant findings.
In pancreatic cancer research, the foundation gave $63,554 to Roswell Park Alliance Foundation for exploring the role of HNF1A in tumor growth and microenvironment dynamics in pancreatic ductal adenocarcinoma. It also awarded $50,000 to the Lustgarten Foundation for a translational convergence program of personalized immunotherapy for pancreatic cancer patients at Johns Hopkins University. The foundation also supports research on treatment resistance. It granted $71,775 to Roswell Park Alliance Foundation for deciphering the drug resistance mechanism of triple-negative breast cancer against doxorubicin by proteome-wide overexpression perturbation. A separate $28,225 award in 2025 went to the same grantee for the same topic. Another $10,291 grant supported a comparison of intermittent fasting with continuous caloric reduction in Black adults of faith.
Typical grant sizes cluster in the mid-five-figure range: p25 is $36,446, median is $50,000, and p75 is $63,554. The foundation also makes smaller and larger awards within an annual program structure, with recent examples ranging from $10,291 to $71,775. The recent record shows repeated support for the same grantee and even the same project theme across multiple years, which points to recurring project funding rather than one-off gifts. The active grant programs describe annual research grants, with one proposal allowed per year and decisions announced about 6–8 weeks after submission. Grants are capped at up to $100,000.
$39K
$1.3M
$84K
$136K
Most grants fall between $36K and $64K, with a median of $50K.
25th Percentile
$36K
Median
$50K
75th Percentile
$64K
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Highly concentrated: few, relatively large grants directed to a small set of specialized cancer research organizations and programs; repeat funding to core grantees with project-specific, translational aims.
Notable grantees: Roswell Park Alliance Foundation, Lustgarten Foundation, Johns Hopkins University (partner institution for funded translational immunotherapy program)
Grantmaking is local and entirely within New York: 100% of grants in the recent data go to recipients in the HQ state, and the top giving state is also NY. The recipient cities named in the grant list are Buffalo and Woodbury. Buffalo appears most often through Roswell Park Alliance Foundation, while Woodbury appears through the Lustgarten Foundation. The country distribution is entirely U.S.-based, with 6 grants in the United States.
Its recent grants center on cancer research with a strong emphasis on pancreatic ductal adenocarcinoma, personalized immunotherapy for pancreatic cancer, and studies of treatment resistance. The active grant programs also cover translational research, preclinical and clinical research, cancer prevention, and cancer treatment mechanisms.
Typical awards fall in the mid-five-figure range. The grant-size distribution shows a p25 of $36,446, a median of $50,000, and a p75 of $63,554. Recent awards also include amounts below that range and up to $71,775.
The pattern suggests repeat support for specific research themes and recipients. Roswell Park Alliance Foundation appears multiple times in the recent grant list, including awards in 2023, 2024, and 2025, and the same triple-negative breast cancer project appears in both 2024 and 2025.
Yes. The active annual research grant programs state that they accept unsolicited proposals, with agencies limited to one proposal per year. The program also says decisions are announced about 6–8 weeks after submission.
The recent grants shown here all go to U.S. recipients, and all listed recipients are in New York. Buffalo appears as a recipient city through Roswell Park Alliance Foundation, and Woodbury appears through the Lustgarten Foundation.
2026
Source: IRS Form 990-PF, fiscal year 2026.
Current and upcoming funding from S A S Foundation for Cancer Research that your nonprofit may be able to apply for.
Who can apply: Agencies/nonprofit organizations conducting cancer research. Only one proposal per agency per year. Full guidelines and forms available in the foundation's application packet.
Deadline: Proposals must be received by November 15 each year (example posted: November 15, 2025).
Track these deadlines, get reminders, and see how well your nonprofit fits — free with a Kindora account.
Create a free accountDeadlines and eligibility are summarized from public sources and may change — always confirm the details on the funder's official application page before applying.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| ROSWELL PARK ALLIANCE FOUNDATION | BUFFALO, NY | $38,736 | 2026 | REPURPOSING AN ANTI-ANXIETY DRUG TO REVERSE IMMUNOSUPPRESSION IN PANCREATIC CANCER |
| ROSWELL PARK ALLIANCE FOUNDATION | BUFFALO, NY | $28,225 | 2025 | DECIPHERING THE DRUG RESISTANCE MECHANISM OF TRIPLE-NEGATIVE BREAST CANCER AGAINST DOXOCRUBICIN BY PROTEOME-WIDE OVEREXPRESSION PERTURBATION |
| ROSWELL PARK ALLIANCE FOUNDATION | BUFFALO, NY | $71,775 | 2024 | DECIPHERING THE DRUG RESISTANCE MECHANISM OF TRIPLE-NEGATIVE BREAST CANCER AGAINST DOXOCRUBICIN BY PROTEOME-WIDE OVEREXPRESSION PERTURBATION |
| ROSWELL PARK ALLIANCE FOUNDATION | BUFFALO, NY | $63,554 | 2024 | EXPLORING THE ROLE OF HNF1A IN TUMOR GROWTH AND MICROENVIRONMENT DYNAMICS IN PANCREATIC DUCTAL ADENOCARNINOMA. |
| ROSWELL PARK ALLIANCE FOUNDATION | BUFFALO, NY | $10,291 | 2024 | comparison of intermittent fasting with continuous caloric reduction in black adults of faith |
| LUSTGARTEN FOUNDATION | WOODBURY, NY | $50,000 | 2023 | A TRANSLATIONAL CONVERGENCE PROGRAM OF PERSONALIZED IMMUNOTHERAPY FOR PANCREATIC CANCER PATIENTS AT JOHNS HOPKINS UNIVERSITY. |
| ROSWELL PARK ALLIANCE FOUNDATION | BUFFALO, NY | $36,446 | 2023 | EXPLORING THE ROLE OF HNF1A IN TUMOR GROWTH AND MICROENVIRONMENT DYNAMICS IN PANCREATIC DUCTAL ADENOCARNINOMA. |
REPURPOSING AN ANTI-ANXIETY DRUG TO REVERSE IMMUNOSUPPRESSION IN PANCREATIC CANCER
DECIPHERING THE DRUG RESISTANCE MECHANISM OF TRIPLE-NEGATIVE BREAST CANCER AGAINST DOXOCRUBICIN BY PROTEOME-WIDE OVEREXPRESSION PERTURBATION
DECIPHERING THE DRUG RESISTANCE MECHANISM OF TRIPLE-NEGATIVE BREAST CANCER AGAINST DOXOCRUBICIN BY PROTEOME-WIDE OVEREXPRESSION PERTURBATION
EXPLORING THE ROLE OF HNF1A IN TUMOR GROWTH AND MICROENVIRONMENT DYNAMICS IN PANCREATIC DUCTAL ADENOCARNINOMA.
comparison of intermittent fasting with continuous caloric reduction in black adults of faith
A TRANSLATIONAL CONVERGENCE PROGRAM OF PERSONALIZED IMMUNOTHERAPY FOR PANCREATIC CANCER PATIENTS AT JOHNS HOPKINS UNIVERSITY.
EXPLORING THE ROLE OF HNF1A IN TUMOR GROWTH AND MICROENVIRONMENT DYNAMICS IN PANCREATIC DUCTAL ADENOCARNINOMA.